Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH), an emerging growth company incorporated in Delaware, filed this Form 8-K on September 10, 2024, reporting events occurring on September 4, 2024. The company is headquartered in Gaithersburg, Maryland, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or aggregate debt levels. The only specific financial metric disclosed is a new debt instrument:
- New Debt: $250,000 promissory note issued to the CEO.
- Interest Rate: 12% per annum.
- Repayment Terms: 12 substantially equal installments over one year.
Material Changes
The material change reported is the entry into a definitive agreement on September 4, 2024, wherein the Company borrowed $250,000 from its Chief Executive Officer, Dr. Anatoly Dritschilo. This transaction formalizes a loan previously extended by the CEO into a structured promissory note.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The primary contingency noted is the Company's obligation to repay the $250,000 principal plus accrued interest to the CEO over the next 12 months. The filing references the full text of the Promissory Note (Exhibit 10.1) for complete terms.
Investor Verification Checklist
- Verify the Company's total outstanding debt and liquidity position to assess the impact of the new $250,000 obligation.
- Review the full text of the Promissory Note (Exhibit 10.1) for any prepayment penalties or default clauses not summarized in the 8-K.
- Confirm the Company's cash burn rate to ensure it can meet the monthly installment payments.
- Check for any related party transaction disclosures in recent 10-Q or 10-K filings regarding Dr. Dritschilo.